Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Interactive Tools
Learning Modules
Presentations
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
ASCO 2018 News - Episode 5
Practice Changes for Use of Immunotherapy in NSCLC
June 2, 2018
EP. 1: OncLive News Network On Location: In Chicago Friday, June 1
EP. 2: OncLive News Network On Location: In Chicago Saturday, June 2
EP. 3: OncLive News Network On Location: In Chicago Sunday, June 3
EP. 4: OncLive News Network On Location: In Chicago Monday, June 4
Now Viewing
EP. 5: Practice Changes for Use of Immunotherapy in NSCLC
EP. 6: ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer
EP. 7: ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer
EP. 8: ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer
EP. 9: ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma
EP. 10: ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma
EP. 11: ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer
EP. 12: ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts
EP. 13: ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies
EP. 14: ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer
EP. 15: KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC
EP. 16: Actual Use of Pembrolizumab and Chemotherapy in NSCLC
EP. 17: CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC
EP. 18: IMPower150: Implications for the Treatment of NSCLC
EP. 19: Important Data in the Squamous NSCLC Population
EP. 20: Impact of Data on the Real-Life Treatment of NSCLC
EP. 21: Tumor Mutational Burden in NSCLC: Should it be Routine?
EP. 22: Optimizing Immunotherapy in the NSCLC Treatment Paradigm
EP. 23: Using Immunotherapy Beyond Progression in NSCLC
EP. 24: Practice Changes for Use of Immunotherapy in NSCLC: Q&A
Related Content:
ASCO 2018 News
Breast Cancer
HER2+ Breast Cancer
Multiple Myeloma
Lung Cancer
Fox Chase Cancer Center Researchers Examine Perceptions of Smoking Stigma Among African American/Black Populations
FDA Approves Amivantamab Plus Chemo for EGFR+ Advanced NSCLC After an EGFR Inhibitor
Dr Rimm on the Limitations of HER2 IHC Assays in Breast Cancer